Background
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist available in both subcutaneous and oral (tablet) formulations. All oral semaglutide tablets are co-formulated with the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) and are manufactured by Novo Nordisk. Three distinct brand-name tablet products are now marketed in the United States:
- Rybelsus: the original oral semaglutide, first FDA-approved September 20, 2019, for type 2 diabetes (available in 3/7/14 mg) (FDA Orange Book, 2024).
- Ozempic tablets: oral semaglutide approved for type 2 diabetes in strengths of 1.5/4/9 mg; “Ozempic tablets” refers to an approved oral product distinct from Rybelsus and from the once-weekly Ozempic injection (FDA Orange Book, 2026).
- Wegovy tablets: high-dose oral semaglutide 25 mg, approved December 22, 2025, as the first oral GLP-1 receptor agonist for chronic weight management (FDA Orange Book, 2025; Khachaturov and Goulis, Diabetes, Obesity and Metabolism, 2026).
Rybelsus and Ozempic tablets share a single FDA label as “oral semaglutide” and differ only in available strengths; Wegovy tablets carry a separate, weight-focused label (FDA Prescribing Information, RYBELSUS and OZEMPIC, 2026; FDA Prescribing Information, WEGOVY, 2026).
Note: this summary reflects US FDA approvals, labelling and pricing. Check HSA registration and local availability before prescribing in Singapore.
Uses (Indications)
Rybelsus and Ozempic tablets are both indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes at high CV risk (FDA Prescribing Information, RYBELSUS and OZEMPIC, 2026). The cardiovascular benefit of oral semaglutide was established in the SOUL trial, which showed a 14% reduction in MACE (hazard ratio 0.86; 95% CI, 0.77–0.96) (McGuire et al., New England Journal of Medicine, 2025).
Wegovy tablets (25 mg) are indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction in adults with obesity, or in adults with overweight plus at least one weight-related comorbid condition; and to reduce the risk of major adverse CV events in adults with established CV disease and obesity or overweight (FDA Prescribing Information, WEGOVY, 2026).
Concomitant use of any semaglutide-containing product with another GLP-1 receptor agonist is not recommended (FDA Prescribing Information, WEGOVY, 2026).
Dosing and Administration
All oral semaglutide tablets share the same critical administration requirements: take once daily on an empty stomach in the morning with no more than 4 oz (120 mL) of plain water, swallow whole, and wait at least 30 minutes before any food, other beverages, or other oral medications (Andersen et al., Drugs, 2021; FDA Prescribing Information, RYBELSUS and OZEMPIC, 2026).
- Rybelsus: 3 mg once daily for 30 days (initiation dose, not effective for glycemic control alone), then 7 mg; may increase to 14 mg after at least 30 days if additional control is needed. Maximum 14 mg daily (FDA Prescribing Information, RYBELSUS and OZEMPIC, 2026).
- Ozempic tablets: 1.5 mg once daily for 30 days (initiation dose), then 4 mg; may increase to 9 mg after at least 30 days if needed. Maximum 9 mg daily (FDA Prescribing Information, RYBELSUS and OZEMPIC, 2026).
- Wegovy tablets: titrated from 3 mg over approximately 12 weeks to a maintenance dose of 25 mg once daily; patients should not take more than one tablet per day (Khachaturov and Goulis, Diabetes, Obesity and Metabolism, 2026).
No dose adjustment is required for renal or hepatic impairment (Andersen et al., Drugs, 2021).
Efficacy
Glycemic control (Rybelsus / Ozempic tablets): In a 26-week monotherapy trial, oral semaglutide reduced HbA1c by 1.2% (7 mg) and 1.4% (14 mg) from a baseline of ~8.0%, versus 0.3% for placebo; 69% and 77% of patients, respectively, achieved HbA1c <7% versus 31% with placebo (FDA Prescribing Information, RYBELSUS and OZEMPIC, 2026).
Weight management (Wegovy tablets): In the 64-week OASIS 4 / Study 7 phase 3 trial, mean body-weight reduction was −13.6% with oral semaglutide 25 mg versus −2.2% with placebo (estimated difference −11.4%; 95% CI, −13.9 to −9.0; p<0.001). Among treated participants, 79.2% achieved ≥5%, 63.0% ≥10%, 50.0% ≥15%, and 29.7% ≥20% weight loss (Khachaturov and Goulis, Diabetes, Obesity and Metabolism, 2026; FDA Prescribing Information, WEGOVY, 2026).
Side Effects
The safety profile is consistent across all oral semaglutide products and the GLP-1 receptor agonist class. Gastrointestinal effects (nausea, vomiting, diarrhea, constipation, and abdominal pain) are the most common adverse events; they are usually mild to moderate, occur mainly during initiation and dose escalation, and tend to be transient. Gradual titration and dietary measures reduce their frequency (Andersen et al., Drugs, 2021; Clements et al., Clinical Pharmacokinetics, 2021). In the OASIS 4 trial of the 25 mg weight-management dose, GI adverse events occurred in 74% of semaglutide-treated versus 42% of placebo-treated participants (Khachaturov and Goulis, Diabetes, Obesity and Metabolism, 2026).
Other considerations across products include:
- Boxed warning for thyroid C-cell tumors; contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (Clements et al., Clinical Pharmacokinetics, 2021).
- Acute pancreatitis: discontinue if suspected; avoid re-initiation after a confirmed episode (Bansal et al., AASLD Practice Guidance, 2025).
- Gallbladder disease (cholelithiasis, cholecystitis) (Bansal et al., AASLD Practice Guidance, 2025).
- Acute kidney injury from volume depletion secondary to GI losses (Bansal et al., AASLD Practice Guidance, 2025).
- Hypoglycemia: rare as monotherapy, but dose reduction of sulfonylureas or insulin may be needed to reduce risk (Andersen et al., Drugs, 2021).
Systematic reviews have found no clear association between GLP-1 receptor agonist use and thyroid cancer, pancreatic cancer, or pancreatitis in humans (Bracchiglione et al., Cochrane Database of Systematic Reviews, 2025).
Comparison Table
| Feature | Rybelsus | Ozempic tablets | Wegovy tablets |
|---|---|---|---|
| Launch / FDA approval | Sept 20, 2019 | May 4, 2026 | Dec 22, 2025 |
| Manufacturer | Novo Nordisk | Novo Nordisk | Novo Nordisk |
| Primary indication | Type 2 diabetes glycemic control; MACE reduction (T2D, high CV risk) | Type 2 diabetes glycemic control; MACE reduction (T2D, high CV risk) | Chronic weight management; MACE reduction (established CVD + obesity/overweight) |
| Strengths | 3 (initiation), 7, 14 mg | 1.5 (initiation), 4, 9 mg | 1.5 (initiation), 4, 9 mg titration |
| Maintenance dose | 7 or 14 mg once daily | 4 or 9 mg once daily | 25 mg once daily |
| Administration | Empty stomach, ≤120 mL water, wait ≥30 min | Empty stomach, ≤120 mL water, wait ≥30 min | Empty stomach, ≤120 mL water, wait ≥30 min |
| Efficacy | HbA1c −1.2% (7 mg) / −1.4% (14 mg) at 26 wk | Same class data as Rybelsus (higher strengths) | −13.6% body weight at 64 wk (OASIS 4) |
| Cost | ~$954 per 28-day supply (2022 estimate) | Not separately reported in retrieved literature | Not separately reported; IRA-negotiated Wegovy (weight-loss dose) max fair price $386/30 days effective Jan 2027 |
Cost Notes
Published cost data specific to the oral tablets remain limited. A 2022 analysis listed Rybelsus at approximately $954 per 28-day supply (Bradley et al., Annals of Pharmacotherapy, 2022). Semaglutide pricing is changing substantially: under the Inflation Reduction Act’s Medicare Drug Price Negotiation Program, the negotiated maximum fair price is $277 per 30-day supply for Ozempic (diabetes dose) and $386 for Wegovy (weight-loss dose), effective January 2027, and a separate voluntary agreement set a Medicare net price of $245 per month for some plans (Dusetzina et al., JAMA, 2026). These figures largely reflect the injectable products; oral tablet-specific negotiated prices were not identified in the retrieved literature.
References
- FDA Orange Book. FDA Orange Book. 2026.
- OZEMPIC. FDA Drug Label. Food and Drug Administration. Updated 2026-01-30. Based on the following primary sources:
- Oral Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes. The New England Journal of Medicine. 2019. Husain M, Birkenfeld AL, Donsmark M, et al.
- Efficacy and Safety of Oral Semaglutide in Patients With Type 2 Diabetes and Moderate Renal Impairment (PIONEER 5): A Placebo-Controlled, Randomised, Phase 3a Trial. The Lancet. Diabetes & Endocrinology. 2019. Mosenzon O, Blicher TM, Rosenlund S, et al.
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. The Journal of the American Medical Association. 2019. Rosenstock J, Allison D, Birkenfeld AL, et al.
- Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 2025. Marx N, Deanfield JE, Mann JFE, et al.
- Beyond GLP-1 Monotherapy: Novel Multi-Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2026. Khachaturov M, Goulis DG. Review.
- Medicare Spending Implications for Semaglutide Under Voluntary Price Agreements. The Journal of the American Medical Association. 2026. Dusetzina SB, Castle G, Han J, Leech AA, Zhu J. Modeling.
- High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management. The Annals of Pharmacotherapy. 2022. Bradley CL, McMillin SM, Hwang AY, Sherrill CH. Review.
- Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes, Obesity & Metabolism. 2023. Aroda VR, Erhan U, Jelnes P, et al.
- What is the evidence regarding the safety of new obesity pharmacotherapies. International Journal of Obesity. 2025. Vidal J, Flores L, Jiménez A, Pané A, de Hollanda A. Review.
- Estimated Sustainable Cost-Based Prices for Diabetes Medicines. JAMA Network Open. 2024. Barber MJ, Gotham D, Bygrave H, Cepuch C. Modeling.